Filed pursuant to Rule 424(b)(5)
(Registration No. 333-240253)
PROSPECTUS SUPPLEMENT
(To Prospectus Dated August 7, 2020)
$100,000,000
Common Shares
8.75% Series D Cumulative Redeemable Perpetual Preferred Shares
(Liquidation Preference $25 Per Share)
Series E Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Shares
(Liquidation Preference $25 Per Share)
Series F Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Shares
(Liquidation Preference $25 Per Share)

We have entered into an amendment, dated October 29, 2021, to our at-the-market equity offering sales agreement, dated May 5, 2021, with DNB Markets, Inc. (“DNB”) and Virtu Americas LLC (“Virtu” and, together with DNB, the “sales agents”) to increase the amount of our common shares, par value $5.00 per share (the “Common Shares”), 8.75% Series D Cumulative Redeemable Perpetual Preferred Shares, par value $1.00 per share, liquidation preference $25.00 per share (the “Series D Preferred Shares”), Series E Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Shares, par value $1.00 per share, liquidation preference $25.00 per share (the “Series E Preferred Shares”) and Series F Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Shares, par value $1.00 per share, liquidation preference $25.00 per share (the “Series F Preferred Shares”) we may offer and sell thereunder by an additional $100,000,000. We refer to the Series D Preferred Shares, the Series E Preferred Shares, and the Series F Preferred Shares collectively in this prospectus supplement as the “Preferred Shares” and our Common Shares and our Preferred Shares collectively as the “Shares.” We have previously sold 2,774,108 of our Common Shares and 974,478 Preferred Shares under the at-the-market equity offering sales agreement pursuant to a separate prospectus supplement dated May 5, 2021, with an aggregate sales price of $50.0 million and which resulted in net proceeds to us of approximately $48.9 million. This prospectus supplement relates to the remaining $100,000,000 available for sale under the at-the-market equity offering sales agreement.
In accordance with the terms of the at-the-market equity offering sales agreement, we may offer and sell our Shares, having an aggregate offering price of up to $100,000,000, from time to time through the sales agents under this prospectus supplement. Sales of the Shares, if any, under this prospectus may be made in sales deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act. Each sales agent will act as sales agent using commercially reasonable efforts to sell on our behalf all of the Shares requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between such sales agent and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
Our common shares are listed on the New York Stock Exchange under the symbol “TNP.” The last reported sale price of our common shares on the New York Stock Exchange on October 28, 2021 was $9.28 per share.
Our Series D Preferred Shares are listed on the NYSE under the symbol “TNP PR D.” The last reported sale price of our Series D Preferred Shares on the NYSE on October 28, 2021 was $24.31 per share.
Our Series E Preferred Shares are listed on the NYSE under the symbol “TNP PR E.” The last reported sale price of our Series E Preferred Shares on the NYSE on October 28, 2021 was $24.28 per share.
Our Series F Preferred Shares are listed on the NYSE under the symbol “TNP PR F.” The last reported sale price of our Series F Preferred Shares on the NYSE on October 28, 2021 was $23.87 per share.
Each sales agent will receive from us a commission equal to 2.0% of the gross sales price per share sold through such sales agent as our sales agent under the at-the-market equity offering sales agreement. The sales agents are not required to sell any specific number or dollar amount of our Shares, but, subject to the terms and conditions of the at-the-market equity offering sales agreement, the sales agents will use their commercially reasonable efforts to sell on our behalf any Shares to be offered by us under the at-the-market equity offering sales agreement. See “Plan of Distribution” beginning on page S-29 in this prospectus supplement.
Investing in our Shares involves risks. See “Risk Factors” beginning on page S-10 of this prospectus supplement, on page 1 of the accompanying prospectus and in the documents incorporated by reference into this prospectus supplement.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
| | |
DNB Markets | | Virtu Financial |
Prospectus Supplement dated October 29, 2021